🇺🇸

US SEC Filing Intelligence

· daily

Mega Contracts Monitor ($100M+) — March 19, 2026

Five mega contracts totaling $1.86B underscore strong federal demand for IT and health services, with Leidos securing the largest $1.06B SSA deal amid 82% outlay progress. All awards are bullish, featuring long durations (avg. potential end 2028+), $1.36B in combined unobligated options, and focus on civilian agencies (SSA, CMS, VA, DHS, Education). Public parents Leidos Holdings, OSI Systems, Oracle, and General Dynamics gain multi-year revenue visibility, though firm-fixed pricing dominates (4/5 contracts).

5 total filings
· daily

High-Value Federal Grants ($5M+) — March 19, 2026

This one-day snapshot of 18 high-value federal contracts totaling $2.9B underscores bullish momentum for IT services and health/security contractors, with Leidos securing the largest $1.1B combined awards from SSA and DHS. Firm fixed price structures dominate (12/18), offering revenue visibility but execution risks, while options provide $2B+ upside potential across portfolios. Institutional investors should prioritize public equities like Leidos (LDOS), OSI Systems (OSIS), and General Dynamics (GD) for steady gov revenue amid long-term extensions to 2033.

18 total filings
· daily

General Federal Contracts — March 19, 2026

Leidos dominates with a $1.06B SSA IT contract (37% of total value), signaling robust civilian IT demand and multi-year revenue stability amid $2.9B in awards. DHS/CBP and VA drive security/IT and medical supply contracts, with 16/18 bullish signals highlighting long-term options worth $2B+ upside. Firm fixed price structures prevail (70% of contracts), exposing winners to cost risks but locking in predictable cash flows through 2026-2033.

18 total filings
· daily

All NASA Contracts — March 19, 2026

NASA's $85.4M obligation to California Institute of Technology for PO.DAAC-2 operations signals stable funding for space science data archiving via JPL FFRDC, with $72.4M already outlayed and $4.2M in unexercised options. As a non-competed, nonprofit contract ending 2026-09-30, it offers neutral direct equity impact but underscores continuity in physical oceanography R&D. Investors face execution risks from task order dependence amid potential NASA priority shifts, with extension potential warranting monitoring.

1 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 19, 2026

Across 50 filings in the USA S&P 500 Consumer Staples stream (though diverse with funds, biotechs, REITs), proxy statements dominate (24/50, neutral sentiment) signaling robust governance ahead of clustered April-May 2026 annual meetings. Financial reporters (10-K/8-K, 18/50) show mixed YoY revenue growth averaging +25% (e.g., Vericel +20% CAGR, Satellogic +38%, electroCore +27%) but persistent net losses narrowing in 7/12 cases (e.g., SentinelOne op inc positive swing). Margin trends mixed with expansions (Signet adj op inc +3.4% FY, Vericel gross 74%) offset by compressions (Signet Q4 -60bps). Capital allocation leans positive: dividend hikes (Signet +17% to $0.35/sh, Modiv $0.10/mth), buybacks (Mount Logan $10M program), accretive M&A (Mount Logan +30% FRE). Forward guidance cautious (Signet FY27 SSS -1.25% to +2.5%) amid Q4 softness, but clinical catalysts in biotechs. Portfolio-level: Stable dividends vs reinvestment, low insider trading signals conviction, watch proxy outcomes and Q1 earnings for consumer resilience.

29 high priority 21 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 19, 2026

Across 50 filings in the USA S&P 500 Industrials stream (broadly including transportation, construction, and adjacent sectors amid mixed data), overarching themes include robust revenue growth in transportation leaders like FedEx (+8% YoY Q3 to $24B) and strategic pivots (UPS prioritizing high-value volume), contrasted by widening losses in biotechs (Eledon +26% net loss YoY) and operational declines (Gemini trading volume -30% QoQ). Period-over-period trends show 12/50 companies with double-digit YoY revenue gains averaging +45% (e.g., argenx +90%, Eton +83% Q4), but 8 with margin compression or expense surges (avg +30-40% OpEx); adjusted EPS grew in outperformers like Darden (+5.4%) and FedEx (+16.4%). Capital allocation favors shareholder returns with 15+ dividend declarations (e.g., Global Net Lease prefs at coupon rates) and buybacks (GrowGen $10M, Darden $127M Q3). Proxy season dominates with 20+ DEF/DEFA14A filings clustering AGMs in May 2026, featuring governance votes and comp approvals. Forward-looking signals positive: FedEx raised FY26 guidance (rev 6-6.5%, EPS $19.30-20.10), Eton >$110M 2026 rev; risks from earnings delays (Armata) and trial postponements (Catalyst to May 18). Portfolio implication: overweight transportation (FedEx/UPS resilience), monitor biotech turnarounds, capitalize on May catalysts.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 19, 2026

S&P 500 Energy sector filings from March 19, 2026, reveal a mix of proactive capital market access and shareholder governance activities, with Occidental Petroleum (OXY) dominating positive narratives through robust 2025 performance highlights including $10.5B operating cash flow, $4.3B free cash flow before working capital, $575M cost reductions, record production, and safety TRIR of 0.07 despite YoY challenging commodity prices. Cheniere Energy (LNG) signals strong liquidity via $1.75B senior notes issuance (5.200% due 2036, 6.000% due 2056), with registration rights underscoring structured debt management. Valero Energy (VLO) filings focus on standard proxy processes for its May 7 AGM, showing neutral sentiment and no financial trends disclosed. Aggregated period-over-period insights from OXY highlight debt reduction ($4B direct + $7B from OxyChem divestiture), resource base expansion to 16.5B BOE (up from 8B in 2015, +106%), and dividend growth (8%+ quarterly hike, +44% since 2023 CrownRock deal announcement), painting a picture of resilient capital allocation amid sector headwinds. Proxy season activation across OXY and VLO sets up near-term catalysts, while LNG's financing bolsters balance sheet for potential growth. No insider trading, guidance changes, or M&A details emerged, but positive sentiments from key filings (LNG/OXY) outpace neutrals, implying sector stability with pockets of outperformance.

3 high priority 2 medium 5 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 19, 2026

Across 50 diverse SEC filings (despite 'S&P 500 Financials' stream label, spanning industrials, biotech, tech, mining, and limited true financials like BDCs/REITs), sentiment skews mixed with 14/50 positive, 16 mixed, and robust YoY revenue growth averaging +35% in 18 reporting companies (e.g., Micron +196%, Cardinal +45%, SUNation +26%) offset by declines in 6 (e.g., Solo Brands -30%, DarioHealth -17%). EBITDA/margin expansions prevalent in 12 cases (e.g., SUNation + to $2.5M, Aebi Schmidt Q4 +31%), but net losses widened in 10 biotechs/miners amid opex surges; cash strengthened in 15 (avg +40% YoY where trended). Capital allocation favors dividends (8 declarations steady, e.g., Chicago Atlantic BDC $0.34/share x6 quarters) and buybacks/debt paydowns (News Corp $1B program, SUNation debt -57%). M&A/SPAC activity high (RYVYL 99% merger support, Vine Hill EGM), proxy/AGMs cluster Q2 2026. Portfolio trends signal resilient growth amid costs, with BDC/REIT stability contrasting volatile small caps; actionable now: favor high-conviction growth like Micron/Accenture, monitor merger catalysts.

23 high priority 27 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 19, 2026

Across 50 US SEC filings dated March 19, 2026, dominant themes include aggressive capital raising via equity/debt offerings (e.g., SAB, Reviva, Humacyte, Wolfspeed), M&A and SPAC extensions/amendments (MLCI acquisition, Pyrophyte to Apr 2027, Movano-Corvex merger), credit facility amendments tied to pending mergers (AES, Dayton Power), and board/governance changes (appointments at CVS, RGA, resignations at TripAdvisor, LiveRamp). Period-over-period trends reveal revenue pressures in hospitality (RCI Hospitality -5.5% YoY to $279.4M, Bombshells -29.2% YoY; Ashford pro forma -1.5% YoY to $1.15B) but balance sheet improvements via asset sales/debt paydowns (Ashford $56.8M sale, DevvStream $5.9M net debt reduction). Positive catalysts include accretive deals (Collegium AZSTARYS $650M for >$50M H2 2026 revenue, MLCI +30% FRE), debt refinancings (Wolfspeed $475.9M lower-cost notes), and JV formations (Horizon $100M). Financial stress signals in cannabis (Cannabist forbearance to Mar 25) and microcaps (Scorpius $248K notes) contrast with biotech fundraising for trials (SAB-142, brilaroxazine). Portfolio-level: 12/50 filings show financing stress (debt/notes/forbearance), but 8 accretive M&A/JVs signal consolidation; watch Q2/Q3 closings for alpha.

50 high priority 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 19, 2026

Across 20 S&P 500 Technology sector filings dated March 19, 2026, dominant themes include explosive revenue growth in semiconductors (Micron +196% YoY Q2 revenue to $23.9B) contrasted with modest IT services expansion (Accenture +8.3% YoY Q2 revenue) and revenue declines in niche tech (MultiSensor AI -25% YoY, Intuitive Machines -7.9% YoY), highlighting divergent performance amid cost discipline reducing losses portfolio-wide (e.g., Mustang Bio net loss -88% YoY, MultiSensor AI -46% YoY). Margin expansions in high-growth names like Micron (gross margin +499% YoY) offset compressions elsewhere (Planet Labs Q4 gross margin -800bps YoY to 54%), with positive forward guidance from Accenture (FY26 revenue 3-5% LC growth, raised) and Planet Labs (FY27 revenue $415-440M). Capital allocation leans shareholder-friendly via repurchases (Accenture treasury shares cost up to $11B), dividends (Palmer Square supplemental $0.01/share, Community Bancorp $0.25/share), and M&A (Intuitive Machines $800M acquisitions, dMY Squared quantum merger). Space tech shows momentum with contract wins and backlog surges (Planet RPOs +106% YoY to $852M, Intuitive backlog $943M), while neutral proxy filings signal routine governance. Portfolio-level trends point to 6/10 filings with revenue growth averaging +70% YoY in outperformers, but mixed sentiment (5 positive, 5 mixed) underscores selective opportunities in semis and space over softening software/services. Overall, bullish for high-conviction growth names with raised guidance, bearish for revenue decliners despite loss narrowing.

10 high priority 10 medium 20 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 19, 2026

Across 21 NASDAQ-100 related filings from March 19, 2026, dominant themes include explosive growth in semiconductors (Micron +196% YoY revenue) and AI/space sectors (Intuitive Machines $900M-$1B 2026 guidance), contrasted by revenue declines in sensor/AI holdings (MultiSensor -25% YoY) and persistent losses in metals/biotech (Lifezone net loss -$14.1M). Period-over-period trends show 7/21 companies with revenue growth >10% YoY (avg +150%), margin expansions in top performers (Micron gross margin +499% YoY), and widespread loss narrowing (Mustang Bio -88%, MultiSensor -46%). Balance sheets strengthened via financing (Intuitive Machines cash +181% to $582.6M, MultiSensor +459% to $24.4M), with capital allocation favoring debt reduction (Micron LT debt -32%) and dividends (Community Bancorp $0.25/share). Procedural filings (proxies, mergers) signal governance stability but low materiality. Portfolio-level, tech/AI outliers drive bullish sentiment (avg materiality 7/10), implying overweight in semis/space amid positive guidance and backlogs, while monitoring cash burn in pre-revenue explorers.

12 high priority 9 medium 21 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 19, 2026

Across 50 filings from the USA Dow Jones 30 intelligence stream (primarily smaller caps and blue-chips like UPS, CVS), a mixed sentiment prevails with 12/50 showing positive revenue/EBITDA growth (avg +40% YoY where reported, e.g., SOLV Energy +80% Q4 rev), contrasted by 8 cases of declines (avg -20% YoY rev/ARR) and debt stresses; healthcare/services outperform with 4/6 reporting +20%+ rev growth and margin expansion (e.g., Vericel 74% gross margin, +33% Adj EBITDA). Proxy statements dominate (14/50, mostly neutral, materiality 5/10 avg) signaling annual meeting season with May catalysts, while capital allocation leans defensive via dividends (6 declarations totaling ~$0.40-0.46/share quarterly). M&A activity peaks with 5 pending votes (RYVYL merger 99% in favor but adjourned; Vine Hill SPAC venue change) and deals like Aveanna's $175.5M acquisition. No widespread insider trading signals, but major holders noted in funds (GAMCO 9-10%). Forward guidance bullish for 7 cos (e.g., SOLV $3.72-3.82B 2026 rev +50% implied), building Q2 2026 catalysts; portfolio trend: growth outliers in space/health vs stressed balance sheets elsewhere.

29 high priority 21 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — March 19, 2026

Across 50 SEC filings for March 19, 2026, key themes include mixed FY2025 financial results with explosive growth in semiconductors (Micron +196% YoY revenue) and biotech (argenx +90% sales), contrasted by declines in digital health (DarioHealth -17% revenue) and energy (Equinor -2.5% revenues). Airlines showed resilience (Republic Airways +13.7% revenue, +32.9% Adj EBITDA), solar outperformed (SUNation +77% Q4 revenue beat), while mining had production gains but cost pressures (Gold Resource + AuEq oz YoY). Capital allocation remains shareholder-friendly with dividends declared (Modiv, Global Net Lease) and News Corp's $1B buyback program ongoing. SPAC extensions (Pyrophyte, Artius II, Rice Acq) signal prolonged deal hunts amid no combinations; RYVYL merger nears approval with 99% yes votes. Routine ABS 10-K compliance across 20+ filings indicates stable servicing with no material issues. Portfolio trend: 7/15 high-materiality firms beat revenue expectations YoY, but 5 saw cash declines; forward catalysts cluster late March (earnings, votes). Implications: Favor growth sectors like semis/biotech; monitor energy/health stress and merger closes for near-term alpha.

37 high priority 13 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 19, 2026

Across 50 SEC filings from the USA S&P 500 Consumer Discretionary stream (broadly encompassing retail, logistics, services), proxy season dominates with 20+ DEF 14A/DEFA14A filings for AGMs clustered in April-May 2026, emphasizing board elections, say-on-pay, and auditor ratifications amid neutral sentiment. Financial performance is polarized: standout YoY revenue growth in retail/logistics (Five Below +22.9% to $4.76B, FedEx Q3 +8% to $24B, Firefly Aerospace +163% to $159.9M) and industrials (Cardinal Infrastructure +45% to $456M, York Space +52% to $386M), contrasted by declines (FiscalNote FY25 -21% to $95.4M, Crawford -2.3% to $1.31B) and widening losses (Larimar Q4 $62.5M vs prior $28.8M). Capital allocation trends positive with buybacks (Aflac $3.5B/33M shares, Crawford $10.5M up from $3.9M), dividend hikes (Aflac +5.2% to $0.61 Q1 2026, Crawford +3.6% to $0.29), and debt reductions (Crawford -24.8% to $151M, Wolfspeed refinancing $475.9M higher-cost notes). Forward guidance largely raised/affirmed (FedEx FY26 rev growth to 6-6.5%, Firefly $420-450M, Cardinal 20%+ EBITDA margin), signaling resilience in consumer demand despite margin pressures (e.g., Cardinal gross margin -80bps to 14%). M&A/JV activity bullish (UniFirst-Cintas merger, Horizon $100M JV), with no notable insider transactions but major holders like GAMCO/Saba in funds. Portfolio-level: 8/15 key financial filers show >20% rev growth avg +60%, but 5 report margin compression avg -100bps; actionable now on catalysts like FedEx spin-off.

27 high priority 23 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 19, 2026

Across 45 filings in the USA S&P 500 Healthcare stream, biotech and healthcare firms (e.g., Assembly, SELLAS, Humacyte, Inhibrx) dominate with narrowed net losses (avg -20% YoY across 6 biotechs) amid R&D ramps (+16% avg YoY) and key partnerships like Gilead's $35M HPI license to Assembly, but cash burns persist requiring shelf registrations and offerings. Broader filings reveal mixed revenue trends (+1.6% YoY sales at Signet, -5.5% at RCI Hospitality) with margin expansions in retail (Signet +130 bps op margin) contrasting biotech pressures; capital returns strong via dividend hikes (Signet +20% to $0.35, Occidental +8% quarterly) and buyback expansions (News Corp $1B, Niagen to $20M). Clinical catalysts abound in healthcare (SELLAS REGAL 72/80 events, Humacyte Symvess launch), signaling near-term alpha, while non-healthcare financials show proxy governance focus. Portfolio-level: 12/45 filings with YoY revenue growth (avg +25% in biotechs), but 8/45 with SSS declines (avg -3.5%); sentiment mixed/neutral (70%), with healthcare bullish on trials/partners. Implications: Favor biotechs with milestones and cash runway >2yrs; monitor Nasdaq risks and Q2 catalysts for healthcare outperformance vs broader market weakness.

25 high priority 20 medium 45 total filings
· daily

Global High-Priority Regulatory Events — March 19, 2026

Across 50 filings in the Global High Priority Market Events stream, dominant themes include routine ABS servicing compliance affirmations (20+ filings, all neutral with no material issues), SPAC extensions and merger adjournments signaling prolonged dealflow, accretive M&A in credit funds, positive insolvency resolutions, and stark contrasts in financial performance with explosive growth in semiconductors (Micron +196% YoY revenue) and biotech (argenx +90% sales) versus declines in digital health (DarioHealth -17% revenue). Period-over-period trends show robust revenue acceleration in 7 high-materiality filers averaging +80% YoY (Micron, argenx, Republic Airways), margin expansions flipping losses to profits in 3 cases, but cash burn persists in pre-revenue SPACs and health tech. Critical developments like Mount Logan's $100M+ asset acquisition (30% FRE boost), Rajeswari Infrastructure's insolvency resolution, and Cannabist Co's forbearance extension highlight takeover, bankruptcy, and regulatory risks resolving positively or extending stress. Portfolio-level patterns reveal sector divergence: tech/biotech outperformance amid financing activity (debt, equity offerings), financial pledges/encumbrances signaling liquidity strains in promoters (Embassy 21% shares), and neutral governance updates in proxies. No widespread insider trading patterns, but capital allocation leans toward growth/reinvestment over returns, with scheduled events clustering in Q2 2026 offering catalysts.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 19, 2026

Two S-1 IPO registration statements filed on March 19, 2026, highlight an active US IPO pipeline targeting autonomous robotics (Exyn Technologies) and nuclear energy (Eagle Nuclear Energy Corp.), reflecting investor interest in AI-driven autonomy and clean energy transitions amid 2026 market recovery. Exyn demonstrates superior operational metrics with positive sentiment (10/10 materiality), including 35% larger volume capture, 44% reduction in survey time (27 to 15 minutes), 97% faster setup (30 to under 1 minute), and 50% cost savings over 10 years in mining case studies, with thousands of autonomous flights since 2016 at Level 4B SAE autonomy. Eagle Nuclear shows neutral sentiment (9/10 materiality) with no revenue or earnings reported through 2025-12-31, but multiple capital raises via Regulation Crowdfunding (2025-04/05) and Private Placements (2024-2025), alongside uranium properties and heavy related-party involvement. No period-over-period financial trends available across filings, but Exyn's operational outperformance vs traditional methods signals strong pre-IPO momentum; Eagle's SPAC ties and offerings indicate funding access despite lacks. Portfolio-level theme: Early-stage IPOs prioritizing tech innovation over current profitability, with Exyn outperforming on metrics (e.g., 1cm accuracy, 2M data points/sec) relative to Eagle's neutral profile. Market implications include potential sector rotation into autonomy/mining/defense and nuclear revival, warranting watch for pricing catalysts.

2 high priority 2 total filings
· daily

US Earnings Financial Results SEC Filings — March 19, 2026

Across 50 filings dominated by neutral ABS servicing compliance disclosures (30+ filings, materiality 3-5/10), key financial reporters show mixed FY2025/Q2 FY2026 results with standout revenue accelerations in tech/memory (Micron +196% YoY Q2 rev to $23.9B) and retail (Ollie's +16.6% sales to $2.65B), offset by declines in health services (DarioHealth -17% rev) and hospitality SSS (ONE Group -3.7%). Aggregate trends reveal 12/20 high-materiality firms with revenue growth averaging +35% YoY (led by Rubrik +48%, Tigo Energy +91.7%), but margins mixed with expansions in 6 (e.g., Micron gross to $17.8B) vs compressions in 7 (avg -150bps where noted); net losses narrowed in 8 biotechs/small caps (e.g., Mustang Bio -88% YoY). Cash positions strengthened in 10 firms (avg +40% YoY, e.g., FedEx to $8B), but deteriorated in 7 (e.g., Lithium Americas liabilities +900%). SPACs (Artius II, Rice) standard pre-deal with trust growth but deficits. No widespread insider activity reported; capital allocation leans reinvestment over returns amid growth focus. Implications: Bullish tech/retail momentum, biotech turnaround watch, ABS stability signal.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 19, 2026

Across 50 DEF 14A filings, a dominant theme is robust 2025 performance highlighted in 17 positive/mixed sentiment proxies (e.g., revenue records at Vericel +20% CAGR, Occidental $10.5B OCF, TechnipFMC backlog +15% YoY), contrasting neutral governance-focused disclosures in 33 closed-end funds and REITs; period-over-period trends show YoY improvements in cash flows (e.g., TechnipFMC FCF +113%), dividends (Aflac +5.2%, BorgWarner +55%), and buybacks ($3.5B at Aflac), with rare declines like Aflac net earnings -29.2% YoY and Tronox 60% dividend cut. Capital allocation leans shareholder-friendly with $4.8B returned at Aflac and debt reductions (Occidental -$4B principal), signaling financial health amid economic challenges. Board refreshments are common (e.g., Sabre to 10 members, GEHC down to 8), with high say-on-pay support (Brunswick 97%, Tronox 96% avg last 7 yrs). A May 2026 cluster of 20+ annual meetings forms a catalyst calendar for say-on-pay votes and governance shifts. Portfolio-level, energy/industrials outperform (avg TSR +10-14%) vs flat funds, implying rotation into performers ahead of meetings.

50 high priority 50 total filings
· daily

US Executive Officer Management Changes SEC — March 19, 2026

Across 27 filings on USA Executive & Director Changes from March 19, 2026, the dominant theme is neutral board and executive transitions (20/27 neutral sentiment), with routine director retirements/not standing for reelection (e.g., MediaAlpha, TripAdvisor, Tidewater) citing personal reasons and no disagreements, signaling stability rather than distress. Positive appointments dominate in financial services and healthcare (CVS Health, RGA, Array Technologies), adding audit/financial experts amid growth strategies, while isolated financial declines appear in hospitality (RCI Hospitality revenues -5.5% YoY to $279.4M, Bombshells -29.2% YoY). Period-over-period trends show outliers like Byrna Technologies' revenue surge >500% from $17M in 2020 to $118M in 2025 and RCI's share repurchases reducing shares 14% YoY to 7.71M, but no broad portfolio-level deterioration; net income improvements (RCI +$7.8M YoY) offset revenue softness. Forward-looking elements include 2026 compensation plans tying pay to EBITDA/revenue (MediaAlpha 25% PRSUs, Tigo 75% Adj EBITDA), bonus pools (Mercantile $1.21M target), and multiple 2026 annual meetings as catalysts. Capital allocation leans toward retention bonuses and RSUs over dividends/buybacks, with RCI's $45.4M FCF flat YoY highlighting reinvestment potential. Overall, low materiality (avg 5.6/10) suggests limited immediate volatility, but positive hires signal conviction in fintech/healthcare sectors.

27 high priority 27 total filings